GlassScriptPhysician profile
Brian J Broker
NPI 1346340007
$1,515.09
in general payments reported to CMS, 2019-2025
14 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.05 · 2020: $14.47 · 2021: $107 · 2022: $96.73 · 2023: $436 · 2024: $248 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $350.51 | 2023-2025 | Dupixent |
| Genzyme Corporation | $265.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $166.15 | 2019-2025 | Nucala |
| Stryker Corporation | $149.64 | 2019-2023 | Scopis Ent |
| Alk-Abello, INC | $114.49 | 2021-2025 | Alternaria Tenuis, Standardized Mite D. Farinae, Timothy, Standardized |
| Optinose US, INC. | $90.93 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $75.69 | 2021-2023 | |
| Aerin Medical INC. | $66.63 | 2020-2025 | |
| Inspire Medical Systems, INC. | $54.75 | 2023-2025 | Inspire |
| Boston Scientific Corporation | $46.64 | 2024-2025 | Farapulse, Watchman Flx |
| Kaleo, INC. | $46.64 | 2019 | |
| Medtronic, INC. | $39.22 | 2022-2024 | Propel |
| Astrazeneca Pharmaceuticals LP | $24.68 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.01 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Broker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.